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e deﬁne a novel mechanism by which integrins
 
regulate growth factor expression and the survival
of carcinoma cells. Speciﬁcally, we demonstrate
 
that the 
 
 
 
6
 
 
 
4 integrin enhances vascular endothelial
growth factor (VEGF) translation in breast carcinoma cells.
The mechanism involves the ability of this integrin to
stimulate the phosphorylation and inactivation of 4E-binding
protein (4E-BP1), a translational repressor that inhibits the
 
function of eukaryotic translation initiation factor 4E (eIF-4E).
The regulation of 4E-BP1 phosphorylation by 
 
 
 
6
 
 
 
4 derives
from the ability of this integrin to activate the PI-3K–Akt
W
 
pathway and, consequently, the rapamycin-sensitive kinase
mTOR that can phosphorylate 4E-BP1. Importantly, we
show that this 
 
 
 
6
 
 
 
4-dependent regulation of VEGF transla-
tion plays an important role in the survival of metastatic
breast carcinoma cells by sustaining a VEGF autocrine
signaling pathway that involves activation of PI-3K and
Akt. These ﬁndings reveal that integrin-mediated activation
of PI-3K–Akt is ampliﬁed by integrin-stimulated VEGF ex-
pression and they provide a mechanism that substantiates
 
the reported role of 
 
 
 
6
 
 
 
4 in carcinoma progression.
 
Introduction
 
An understanding of the mechanisms that sustain the survival
of tumor cells in adverse physiological conditions is one of the
most important problems in cancer biology. As argued recently,
cancer progression is an evolutionary process that selects for
cells that exhibit the capacity for survival in environmental
conditions not present in normal tissue (Fearon, 1999;
Hanahan and Weinberg, 2000). One survival strategy used by
tumor cells is the secretion of proteins that elicit an angiogenic
response, such as vascular permeability factor or vascular
endothelial growth factor (VEGF).* VEGF appears to be an
essential factor for the progression of many solid tumors
(Shweiki et al., 1992; Brown et al., 1999; Dvorak et al., 1999).
It is widely assumed that the function of VEGF produced by
tumor and tumor stromal cells is to stimulate angiogenesis
by acting in a paracrine fashion on vicinal endothelium
(Hanahan and Folkman, 1996; Brown et al., 1999). Another
mechanism for tumor cell survival is the establishment of
autocrine signaling loops that act on tumor cells directly (Scot-
landi et al., 1996; Tokunou et al., 2001; Wong et al., 2001).
Although the significance of this mechanism has been over-
shadowed by angiogenesis, recent studies have substantiated the
importance and necessity of such signaling loops for tumor
survival (Scotlandi et al., 1996; Bachelder et al., 2001;
Tokunou et al., 2001; Wong et al., 2001). Indeed, this
mechanism probably contributes to the ability of cells to
survive in hypoxic, poorly vascularized regions of tumors. In
this direction, we described recently the existence of a VEGF
autocrine signaling pathway in metastatic breast carcinoma
cells that is essential for their survival (Bachelder et al., 2001).
An important issue that arises from the contribution of
VEGF autocrine signaling to tumor survival is an under-
standing of the mechanisms that regulate VEGF expression.
Such mechanisms are important not only for VEGF signaling
in tumor cells, but also for angiogenesis as well. Clearly,
hypoxia is a strong inducer of VEGF transcription and
mRNA stability (von Marschall et al., 2001), but other factors
are likely to be involved. Of note, our finding that the 
 
 
 
6
 
 
 
4
integrin can promote the survival of breast carcinoma cells in
stress conditions is intriguing (Bachelder et al., 1999b) and
raised the novel possibility that a specific integrin, which has
been implicated in cancer progression, could regulate VEGF
expression. This possibility is substantiated by the finding
reported here that the ability of the 
 
 
 
6
 
 
 
4 integrin to promote
survival is VEGF dependent.
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The results described above prompted us to investigate the
relationship between the 
 
 
 
6
 
 
 
4 integrin and VEGF expres-
sion. We observed that the expression and signaling proper-
ties of this integrin have no impact on steady-state VEGF
mRNA levels. Surprisingly, however, we detected a signifi-
cant influence of 
 
 
 
6
 
 
 
4 on VEGF translation and protein ex-
pression in these cells, an observation that reveals the ability
of this integrin to regulate translation. The mechanism by
which 
 
 
 
6
 
 
 
4 regulates VEGF expression involves its ability
to stimulate the phosphorylation of 4E-binding protein (4E-
BP1). 4E-BP1 is phosphorylated by mammalian target of
rapamycin (mTOR), a protein kinase whose catalytic do-
main is structurally related to that of phosphatidylinositol
3-kinase (PI-3K) (Dennis et al., 1999; Schmelzle and Hall,
2000). Phosphorylation of 4E-BP1 by mTOR disrupts its
binding to eukaryotic translation initiation factor eIF-4E,
which is present in rate-limiting amounts in most cells (De
Benedetti and Harris, 1999; McKendrick et al., 1999). eIF-
4E plays a critical role in the recruitment of the translational
machinery to the 5
 
 
 
 end of mRNA, which is demarcated by
an m7GpppN cap (where m is a methyl group and N is any
nucleotide) (Raught and Gingras, 1999). The m7 cap is es-
sential for the translation of most mRNAs including VEGF
(De Benedetti and Harris, 1999; Raught and Gingras,
1999). Dissociation of 4E-BP1 from eIF-4E enables eIF-4E
to initiate translation (Gingras et al., 1999, 2001b). The reg-
ulation of 4E-BP1 phosphorylation by 
 
 
 
6
 
 
 
4 derives from
the ability of this integrin to activate the PI-3K–Akt path-
way and, consequently, mTOR. Our findings reveal a novel
mechanism of tumor cell survival and they highlight the
ability of a specific integrin to regulate protein translation by
influencing eIF-4E activity.
 
Results
 
The ability of the 
 
 
 
6
 
 
 
4 integrin to promote the survival 
of carcinoma cells is VEGF dependent
 
To examine the hypothesis that the ability of the 
 
 
 
6
 
 
 
4 inte-
grin to promote survival is VEGF dependent, we used
MDA-MB-435 cells, which lack expression of this integrin.
Stable expression of 
 
 
 
6
 
 
 
4 in these cells enhances their abil-
ity to survive in stressful conditions (Bachelder et al.,
1999b). Importantly, however, expression of 
 
 
 
6
 
 
 
4 does not
alter the expression of other integrin subunits in these cells
and does not influence their adhesion to matrix (Shaw et al.,
1997). As shown in Fig.1 A, a significant level of apoptosis
was observed after 24 h of serum deprivation in the parental
MDA-MB-435 cells and mock transfectants, as well as in
transfectants that express 
 
 
 
6
 
 
 
4 containing a cytoplasmic
domain deletion of the 
 
 
 
4 subunit that lacks the ability to
signal (Shaw et al., 1997). Stable subclones that express the
intact 
 
 
 
6
 
 
 
4 integrin, however, were protected from apopto-
sis under these conditions. Based on these results and our
previous finding that the survival of metastatic breast carci-
noma cells is dependent on VEGF, we used a VEGF anti-
sense oligonucleotide to reduce VEGF expression in the
MDA-MB-435/
 
 
 
4 transfectants and assessed the impact of
reducing VEGF expression on their survival (Fig. 1, B and
C). The VEGF antisense oligonucleotide reduced VEGF
protein expression significantly in the 
 
 
 
4 transfectants (Fig.
1 C). As shown in Fig. 1 B, this reduction in VEGF expres-
sion abrogated the survival-enhancing effect of 
 
 
 
6
 
 
 
4 under
conditions of serum deprivation.
 
The 
 
 
 
6
 
 
 
4 integrin increases VEGF protein but not 
mRNA expression
 
Given that the survival effect of 
 
 
 
6
 
 
 
4 expression is VEGF
dependent, the novel possibility arose that VEGF expression
could be regulated by this integrin. VEGF expression can be
regulated at the level of both transcription and mRNA sta-
bility (Nabors et al., 2001; von Marschall et al., 2001),
mechanisms that would alter the steady-state levels of VEGF
Figure 1. The  6 4-mediated survival of breast carcinoma cells is 
VEGF dependent. (A) Parental, mock (clone 1, 6D2; clone 2, 6D7), 
 4- CYT–expressing (cytoplasmic tail deletion mutant), and  4 
integrin–expressing (clone 1, 3A7; clone 2, 5B3) MDA-MB-435 
subclones were maintained in low serum (0.5% FBS) medium for
24 h. To assess the level of apoptosis, these cells were stained with 
annexin V–FITC and propidium iodide (PI), and analyzed on a 
Becton Dickinson flow cytometer using CellQuest software. The 
percentage of annexin-positive, PI-negative cells (  SD) is indicated. 
Results were obtained from three independent experiments. Apoptosis 
was minimal in the presence of 10% FBS (unpublished data). 
(B) Mock-transfected clone 6D7 and  4 integrin– (clone 1, 3A7; 
clone 2, 5B3) expressing MDA-MB-435 subclones were transiently 
transfected with VEGF sense or antisense oligonucleotides and 
maintained in low serum (0.5% FBS) medium. After 24 h, the level 
of apoptosis in these cells was assessed as described above. The 
data are presented as the mean difference (  SD) in annexin positivity 
between mock-transfected and  6 4-expressing MDA-MB-435 
cells. Similar results were observed in two separate experiments. 
(C) The relative amount of VEGF protein in extracts obtained from 
the MDA-MB-435/ 4 cells transfected with either the VEGF sense 
(S) or antisense (AS) oligonucleotide was determined by immuno-
blotting using a polyclonal anti-VEGF immune serum. 
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mRNA. In addition, regulation can also occur at the level of
VEGF translation (Kevil et al., 1996; Akiri et al., 1998;
Stein et al., 1998). As shown in Fig. 2 A, quantitative analy-
sis of VEGF mRNA levels in two clones of MDA-MB-435/
mock and 
 
 
 
4 transfectants using real-time PCR revealed no
significant difference in the steady-state mRNA levels in
these two populations. However, we detected a substantial
increase in VEGF protein expression in the MDA-MB-435/
 
 
 
4 transfectants relative to either the parental cells, mock
 
transfectants, or cells that express a cytoplasmic domain de-
letion of the 
 
 
 
4 subunit (
 
 
 
4-
 
 
 
CYT) (Fig. 2 B). These re-
sults indicate that the 
 
 
 
6
 
 
 
4 integrin regulates VEGF pro-
tein expression. It is also worth noting that the level of
apoptosis observed in these populations in response to serum
deprivation correlates inversely with their expression of
VEGF (Fig. 1 A and Fig. 2 B).
To substantiate the regulation of VEGF expression by
 
 
 
6
 
 
 
4, integrin-specific antibodies were used to cluster either
 
 
 
6
 
 
 
4 or 
 
 
 
5
 
 
 
1 and the effects of integrin-mediated cluster-
ing on VEGF expression were assessed by immunoblotting.
Of note, the MDA-MB-435/
 
 
 
4 transfectants express equiv-
alent levels of 
 
 
 
6
 
 
 
4 and 
 
 
 
5
 
 
 
1 (unpublished data). An 
 
 
 
6-
specific antibody (mAb 2B7) was used to cluster the 
 
 
 
6
 
 
 
1
integrin in the mock transfectants and the 
 
 
 
6
 
 
 
4 integrin in
the 
 
 
 
4 transfectants, a 
 
 
 
4-specific antibody (mAb A9) was
used to cluster the 
 
 
 
6
 
 
 
4 integrin in the 
 
 
 
4 transfectants,
and an 
 
 
 
5-specific antibody (mAb Sam1) was used to cluster
 
 
 
5
 
 
 
1 in both the mock and 
 
 
 
4 transfectants. A substantial
induction of VEGF expression was observed upon 
 
 
 
6
 
 
 
4 in-
tegrin clustering in the 
 
 
 
4 transfectants but not in the mock
transfectants, and no induction was seen in response to
 
 
 
5
 
 
 
1 clustering (Fig. 2 C). Importantly, the induction of
VEGF expression that occurs in response to 
 
 
 
6
 
 
 
4 clustering
was inhibited by cycloheximide (Fig. 2 C). This result, to-
gether with the real-time PCR data (Fig. 2 A), indicates that
 
 
 
6
 
 
 
4 is influencing VEGF translation.
To obtain more definitive evidence that 
 
 
 
6
 
 4 is regulat-
ing VEGF translation, we performed polysome analysis of
the VEGF message. mRNA isolated from the MDA-MB-
435/mock and  4 transfectants was fractionated on a sucrose
gradient (Fig. 3 A) and the relative amount of VEGF mRNA
in each fraction was determined by real-time PCR (Fig. 3 B).
As shown in Fig. 3 B, a striking difference in the distribution
of VEGF mRNA was evident in the two populations of cells.
In the MDA-MB-435/ 4 transfectants, VEGF mRNA frac-
tionated in the heavy polysomal region, whereas in the mock
transfectants, the majority of VEGF mRNA was associated
with light polysomal to ribosomal subunit fractions. This re-
sult indicates that the translation of VEGF in the MDA-
MB-435/ 4 transfectants is cap dependent.
Identification of an  6 4 integrin–mediated signaling 
pathway that regulates VEGF expression
Our finding that  6 4 regulates the cap-dependent transla-
tion of VEGF prompted us to assess the ability of this inte-
grin to stimulate the activity of the eIF-4E translation initia-
tion factor. The  6 4 integrin is a potent activator of the
PI-3K–Akt signaling pathway in MDA-MB-435 and other
carcinoma cells (Shaw et al., 1997; Bachelder et al., 1999a;
Gambaletta et al., 2000; Nguyen et al., 2000; Hintermann
et al., 2001), and this pathway has been linked to the regula-
tion of protein translation. Specifically, the serine/threonine
kinase mTOR is activated by Akt-mediated phosphorylation
events (Sekulic et al., 2000). Phosphorylation of 4E-BP1 by
mTOR disrupts its binding to eIF-4E, enabling eIF-4E to
initiate translation of VEGF and other molecules (De Bene-
detti and Harris, 1999). We hypothesized, based on this
information, that  6 4 regulates 4E-BP1 phosphorylation
and, as a consequence, VEGF expression. Initially, we as-
Figure 2. Expression of the  6 4 integrin increases VEGF protein 
but not steady-state mRNA. (A) The amount of VEGF mRNA in 
extracts obtained from mock- (clone 1, 6D2; clone 2, 6D7) and  4 
integrin– (clone 1, 3A7; clone 2, 5B3) transfected MDA-MB-435 
subclones was quantified by real-time PCR. The data are presented 
as the mean ratio of VEGF to  -actin mRNA (  SD) obtained from 
triplicate samples. (B) Parental (435), mock (clone 1, 6D2; clone 2, 
6D7),  4- CYT–expressing (clone 1E10), and  4 integrin–expressing 
(clone 1: 3A7, clone 2: 5B3) MDA-MB-435 subclones were cultured 
in low serum (0.5% FBS) medium for 24 h. Extracts of these cells 
containing equivalent amounts of protein were analyzed for their 
relative expression of VEGF and actin by immunoblotting. Similar 
results were observed in four independent experiments. (C) Mock 
(clone 6D7) and  4 integrin–expressing (clone 3A7) MDA-MB-435 
subclones were maintained in low serum (0.5% FBS) medium for 24 h. 
These cells were detached with trypsin and incubated with integrin-
specific antibodies ( 6 integrin, 2B7;  4 integrin, A9;  5 integrin, 
Sam1) or IgG for 30 min in suspension and allowed to adhere on 
anti-IgG–coated plates for 60 min before lysis. In addition, cells 
were preincubated in cycloheximide (CHX) at a concentration of 10 
 g/ml for 30 min and then incubated with either the  6 or  4 
integrin antibodies in the presence of cycloheximide. Extracts of 
these cells containing equivalent amounts of protein were analyzed 
for their relative expression of VEGF and actin by immunoblotting. 
Similar results were observed in two independent experiments.168 The Journal of Cell Biology | Volume 158, Number 1, 2002
sessed the steady-state phosphorylation levels of 4E-BP1 and
S6 kinase (p70
S6K), which are both downstream targets of
mTOR, in cells that had been serum deprived for 24 h. In-
deed, a marked increase in the level of phosphorylation of
4E-BP1 (on Ser65) and p70
S6K (on Thr389) was evident in
the MDA-MB-435/ 4 transfectants relative to either the
mock transfectants or the parental cells (Fig. 4 A). Phosphor-
ylation of Ser65 of 4E-BP1 has been shown to be critical for
dissociation of 4E-BP from eIF-4E (Gingras et al., 2001a).
The reduced expression of 4E-BP1 in the  4 transfectants
compared with the mock transfectants that is apparent in
Fig. 4 A may reflect the possibility that the 4E-BP Ab does
not recognize the hyperphosphorylated form of the protein
as well as it recognizes the hypophosphorylated form.
The involvement of eIF-4E in VEGF translation was con-
firmed by the expression of an antisense eIF-4E oligonucle-
otide in the MDA-MB-435/ 4 transfectants. As shown in Fig.
4 B, expression of this oligonucleotide reduced the level of
VEGF protein significantly. In contrast, expression of the full-
length eIF-4E cDNA increased the VEGF protein level by ap-
proximately twofold. These results, together with the polysome
analysis data (Fig. 3), indicate that  6 4 regulates VEGF ex-
pression by eIF-4E–mediated, cap-dependent translation.
To confirm the specificity of the  6 4 integrin in mTOR
signaling, the effects of integrin-mediated clustering on 4E-
BP1 phosphorylation were assessed. A substantial induction
of Akt, 4E-BP1, and p70
S6K phosphorylation was observed
upon  6 4 integrin clustering in the  4 transfectants but
not in the mock transfectants (Fig. 4 C). In contrast, cluster-
ing of the  5 1 integrin did not stimulate phosphorylation
of these molecules in either the mock or  4 transfectants.
Collectively, these data demonstrate the preferential ability
of the  6 4 integrin to regulate the mTOR signaling path-
way and, more importantly, the phosphorylation of 4E-BP1.
Figure 3. Polysome analysis of VEGF mRNA. (A) The distribution 
of RNA from MDA-MB-435/ 4 and mock transfectants that had 
been fractionated on sucrose gradients as described in the Materials 
and methods was determined by measuring the A254 of each fraction. 
(B) The relative VEGF mRNA content of each sucrose gradient fraction 
was measured by real-time PCR as described in the Materials and 
methods. Fraction 1 contains unbound RNA present in the ribo-
nucleoprotein fraction, fraction 2 contains 40S and 60S monosomes, 
fraction 3 contains 80S monosomes, fractions 4–7 contain light 
polysomes, and fractions 8–12 contain heavy polysomes. The data 
are presented as the mean ratio of VEGF to  -actin mRNA (  SD) 
obtained from triplicate samples. Similar results were obtained from 
three independent experiments.
Figure 4. The  6 4 integrin stimulates the phosphorylation of 
Akt, 4E-BP1, and p70
S6K. (A) MDA-MB-435 parental cells, mock 
transfectants, and  4 transfectants were maintained in medium 
containing low serum (0.5% FBS) for 24 h. The phosphorylation status 
of 4E-BP1 on Ser 65 and S6K on Thr 389 was assessed in extracts 
from these cells using phosphospecific antibodies as described in 
the Materials and methods. In addition, the total amount of 4E-BP1 
and p70
S6K in these extracts was assessed by immunoblotting. (B) The 
MDA-MB-435/ 4 cells were transiently transfected with either an 
eIF-4E sense (S) or antisense (AS) oligonucleotide, or a full-length 
eIF-4E cDNA (4E). Extracts of these cells containing equivalent 
amounts of protein were analyzed for their relative expression of 
VEGF and actin by immunoblotting. (C) MDA-MB-435 mock (clone 
6D7) and  4 (clone 3A7) transfectants were maintained in low serum 
(0.5% FBS) medium for 24 h. These cells were detached with 
trypsin and incubated with integrin-specific antibodies ( 6 integrin, 
2B7;  6 integrin, GOH3;  5 integrin, Sam1;  4 integrin, A9) or IgG 
for 30 min as described in the legend to Fig. 2. The phosphorylation 
status of 4E-BP1 (Ser 65), S6K (Thr 389), and Akt (Ser 473) was 
assessed in extracts from these cells using phosphospecific antibodies. 
Similar results were observed in four independent experiments. Integrin ( 6 4) regulation of VEGF and carcinoma survival | Chung et al. 169
To establish that PI-3K and mTOR are required for 4E-
BP1 phosphorylation and VEGF expression, we performed
the antibody clustering experiments in the presence of the
PI-3K–specific inhibitor LY294002 and the mTOR-specific
inhibitor rapamycin (Fig. 5). As shown in Fig. 5 A, both of
these inhibitors blocked the  6 4-mediated induction of
4E-BP1 phosphorylation and VEGF expression. Although
rapamycin did not block Akt phosphorylation, LY294002
did inhibit its phosphorylation, confirming that Akt acts up-
stream of mTOR and downstream of PI-3K (Fig. 5 A).
These inhibitors did not block the phosphorylation of
ERK1 and ERK2 (Fig. 5 A).
Finally, we investigated the importance of the mTOR
pathway in survival, using rapamycin and LY294002. As
shown in Fig. 5 B, rapamycin treatment increased the apop-
tosis of the MDA-MB-435/ 4 transfectants fivefold and
LY294002 treatment increased their apoptosis eightfold.
These results indicate that the PI-3K–mTOR pathway is
critical for the survival of these cells.
Identification of a specific tyrosine residue in the  4 
cytoplasmic domain required for  6 4 stimulation of 
4E-BP1 phosphorylation and VEGF expression
Recently, a critical tyrosine residue (Y1494) was identified
in the third fibronectin type III repeat of the  4 cytoplasmic
domain, and this tyrosine was shown to be essential for acti-
vation of PI-3K by  6 4 (Shaw, 2001). To assess the im-
portance of Y1494 in 4E-BP1 phosphorylation and VEGF
expression, stable subclones of MDA-MB-435 cells were
generated that expressed  6 4 containing a Y1494F muta-
tion. As shown in Fig. 6 A, VEGF protein expression was
barely detectable in these transfectants compared with the
wild-type transfectants. Also, the steady-state level of 4E-
BP1 phosphorylation was substantially lower in the Y1494F
mutant transfectants than in the wild-type  4 transfectants.
Interestingly, these mutant transfectants also exhibited an
Figure 5. Stimulation of 4E-BP1 phosphorylation, VEGF expression, 
and survival by the  6 4 integrin requires PI-3K and mTOR. 
(A) MDA-MB-435  4 transfectants (clone 3A7) were incubated with 
either DMSO ( ), the PI-3K inhibitor LY 294002 (10  M) (LY), or 
the mTOR-specific inhibitor rapamycin (50nM) (RPA) for 30 min 
and then incubated with either IgG or the  6 integrin antibody 2B7 
as described in the legend to Fig. 2. Extracts of these cells were 
immunoblotted for phospho–4E-BP1 (Ser65), VEGF, phospho-Erk 
(recognizing phosphorylated isoforms of ERK1 and ERK2), phospho-
Akt (Ser 473), and total Akt. Similar data were obtained in three 
experiments. (B) MDA-MB-435  4 transfectants (clone 3A7) were 
maintained at low serum (0.5%) medium for 24 h in the presence of 
either rapamycin (50nM) (RPA), LY 294002 (10  M) (LY), or DMSO 
( ). Apoptosis was assayed as described in the Materials and 
methods and is reported as the percentage of annexin V–FITC-
positive, PI-negative cells. The data shown are mean values (  SD) 
of a representative experiment performed in triplicate.
Figure 6. Y1494 in the  4 cytoplasmic domain is required for 
 6 4 stimulation of 4E-BP1 phosphorylation, VEGF expression, 
and survival. (A) MDA-MB-435 parental cells (435), mock transfectants 
(clone 6D7), wild-type  4 transfectants (clone 3A7), and Y1494F 
mutant transfectants (clone E1h) were maintained in low serum 
(0.5% FBS) for 24 h. Extracts from these cells were analyzed by 
immunoblotting to assess the relative expression of VEGF and 
4E-BP1 phosphorylation. The relative amount of actin was also 
determined as a control for protein loading. Similar results were 
obtained in three experiments. (B) Aliquots of the same cell 
populations described in A were assayed for the level of apoptosis 
after a 24-h incubation in low serum (0.5% FBS) medium. Apoptosis 
was assayed as described in the Materials and methods and is 
reported as the percentage of annexin V–FITC-positive, PI-negative 
cells. The data shown are mean values (  SD) of three experiments 
performed in triplicate.170 The Journal of Cell Biology | Volume 158, Number 1, 2002
eightfold higher level of apoptosis than the wild-type  4
transfectants in response to serum deprivation (Fig. 6 B).
The apoptosis of the mutant cells was reduced substantially
by the addition of recombinant VEGF (Fig. 6 B), a result
that substantiates the importance of VEGF in the survival of
these cells. Together, these findings highlight the impor-
tance of the  4 cytoplasmic domain and PI-3K signaling in
the regulation of VEGF expression and tumor cell survival.
Expression of constitutively active Akt stimulates 
4E-BP1 phosphorylation and VEGF expression in
the absence of  6 4 signaling
The hypothesis that activation of Akt is a major determinant
for the stimulation of 4E-BP1 phosphorylation and VEGF
expression was assessed by expressing a constitutively active
Akt construct in MDA-MB-435 cells that are deficient in
 6 4 signaling. For this purpose, we used MDA-MB-435/
mock transfectants that lack  6 4 expression and the
MDA-MB-435/ 4 Y1494F transfectants, described above,
which are deficient in  6 4-mediated activation of PI-3K.
These cells were infected with adenoviruses that encoded ei-
ther a myristoylated Akt (Myr-Akt) construct or  -galactosi-
dase as a control. As shown in Fig. 7, expression of Myr-Akt
stimulated 4E-BP1 phosphorylation and VEGF expression
substantially in both populations of transfectants in compar-
ison to cells that expressed  -galactosidase. This result indi-
cates the critical importance of Akt activation by  6 4 for
stimulating VEGF expression.
 6 4 regulates 4E-BP1 phosphorylation, VEGF 
expression, and survival in carcinoma cells that express 
this integrin endogenously
Given that the data reported above are based on the exoge-
nous expression of  6 4 in  6 4-deficient carcinoma cells,
we sought to extend our findings to cells that express this in-
tegrin endogenously, a pattern that is typical of most carci-
noma cells. For this purpose, we used MDA-MB-231 breast
carcinoma cells because they express the  6 4 and  5 1 in-
tegrins (Plopper et al., 1998; Mukhopadhyay et al., 1999;
Saad et al., 2000). Initially, we confirmed that the survival of
these cells is dependent on their expression of VEGF. As
shown in Fig. 8 A, expression of a VEGF antisense oligonu-
cleotide in these cells (Bachelder et al., 2001) resulted in an
approximate fourfold increase in annexin V staining upon
serum starvation compared with either untreated cells or
cells that expressed the sense oligonucleotide.
To establish a role for  6 4 in regulating VEGF expres-
sion and survival rigorously, we used a small interfering
Figure 7. Expression of a constitutively active Akt construct 
mimics the effects of  6 4 integrin expression and signaling. 
MDA-MB-435 mock transfectants (clone 6D7) and Y1494F mutant 
transfectants (clone E1h) were infected with adenoviruses that 
expressed either  -galactosidase or Myr-Akt as described in the 
Materials and methods. Subsequently, the cells were incubated in 
low serum (0.5% FBS) medium for 24 h. Extracts of these cells were 
immunoblotted to assess the relative phosphorylation of Akt and 
4E-BP1, as well as total expression of VEGF and actin.
Figure 8.  6 4 regulates 4E-BP1 phosphorylation, VEGF 
expression, and survival in carcinoma cells that express this 
integrin endogenously. (A) Parental MDA-MB-231 cells and cells 
transfected with antisense or sense VEGF oligonucleotides were 
maintained in low serum (0.5% FBS) medium for 24 h. Apoptosis 
was assayed as described in the Materials and methods and is 
reported as the percentage of annexin V–FITC-positive, PI-negative 
cells. The data shown are mean values (  SD) of two separate 
experiments performed in triplicate. (B) MDA-MB-231 cells were 
left untreated (UNT) or were transfected with either an RNAi specific 
for the  4 integrin (si- 4) or the corresponding inverted sequence 
(si-inv). After 72 h, the cells were placed in medium containing low 
serum (0.5% FBS) for an additional 24 h and then extracted. Extracts 
of these cells were immunoblotted as described in the legend to 
Fig. 4 to assess expression of  4 integrin, VEGF, and actin, as well 
as the phosphorylation of 4E-BP1. Similar results were observed in 
three independent trials. (C) Apoptosis was assessed in the same 
populations of cells and is reported as the percentage of annexin
V–FITC-positive, PI-negative cells. The data shown are mean values 
(  SD) of three independent experiments performed in triplicate. 
(D) MDA-MB-231 cells were maintained in low serum (0.5% FBS) 
medium for 24 h and harvested by trypsin treatment. The suspended 
cells were incubated with integrin-specific antibodies ( 4 integrin, 
A9;  6 integrin, 2B7;  5 integrin, Sam1) or IgG for 30 min in 
suspension and allowed to adhere on anti-IgG–coated plates for 30 
min. Extracts of these cells were immunoblotted with phosphospecific 
antibodies to assess the relative phosphorylation of Akt and 4E-BP1, 
as well as with antibodies specific for VEGF and actin. Similar 
results were obtained in five experiments. Integrin ( 6 4) regulation of VEGF and carcinoma survival | Chung et al. 171
RNA (RNAi) approach to inhibit  4 expression in MDA-
231 cells. RNAis specific for the  4 subunit and the corre-
sponding inverted sequence were designed and expressed in
these cells by transfection. The cells were maintained in low
serum (0.5%) for 24 h after transfection and then analyzed.
As shown in Fig. 8 B, cells transfected with the RNAi spe-
cific for  4 exhibited a significant reduction in  4 expres-
sion in comparison with either untransfected cells or cells
transfected with the inverted sequence. Importantly, the re-
duction in  4 expression by RNAi coincided with a marked
reduction in 4E-BP1 phosphorylation and in the steady-
state level of VEGF (Fig. 8 B), as well as an approximate
threefold increase in annexin V staining (Fig. 8 C). These re-
sults link  6 4 expression directly to 4E-BP1 phosphoryla-
tion, VEGF expression, and survival in a carcinoma cell line
that expresses endogenous  6 4.
Subsequently, we performed antibody clustering experi-
ments to substantiate the regulation of VEGF expression by
 6 4 (Fig. 8 D). Clustering of the  6 4 integrin with ei-
ther an  6 integrin–specific antibody (mAb 2B7) or a  4
integrin–specific antibody (mAb A9) stimulated the phos-
phorylation of 4E-BP1 and Akt, and increased VEGF ex-
pression. In contrast, no induction of VEGF expression or
stimulation of either 4E-BP1 or Akt phosphorylation was
observed upon clustering with an  5 integrin–specific anti-
body (mAb Sam1) or IgG.
Discussion
This study establishes a novel mechanism by which integrins
regulate growth factor expression. Specifically, our findings
demonstrate the ability of a specific integrin ( 6 4), which
has been implicated in carcinoma progression (Mercurio and
Rabinovitz, 2001), to stimulate the translation of VEGF and
sustain a VEGF autocrine loop that is essential for survival.
More specifically, we define a signaling pathway regulated by
 6 4 that involves the preferential ability of this integrin to
stimulate the phosphorylation of 4E-BP1 by activating the
PI-3K–Akt pathway. As shown previously, this phosphoryla-
tion event dissociates 4E-BP1 from eIF-4E, enabling this key
elongation factor to mediate the translation of VEGF and
other functionally important molecules (De Benedetti and
Harris, 1999; Gingras et al., 1999, 2001b; McKendrick et
al., 1999). Moreover, the polysome analysis and antisense
eIF-4E results we provide indicate that  6 4 stimulation of
VEGF translation is cap dependent and probably doesn’t in-
volve the internal ribosome entry sites that are present in the
VEGF mRNA (Huez et al., 1998; van der Velden and
Thomas, 1999). Our data extend earlier reports on the in-
volvement of eIF-4E, VEGF, and  6 4 in carcinoma pro-
gression by linking these molecules in a common signaling
pathway that promotes tumor survival. Furthermore, they
reveal a role for integrins in regulating growth factor expres-
sion by stimulating protein translation.
An important and novel aspect of our findings is that they
add a new dimension to the understanding of how integrins
promote cell survival. The widely accepted notion is that in-
tegrins, often in concert with growth factor receptors, acti-
vate specific signaling pathways that sustain survival (Taylor
et al., 1999; Liu et al., 2000). We demonstrate here that the
survival function of integrins may not only be mediated by
the activation of a key survival kinase such as Akt and the
consequent effects of Akt on apoptotic signaling (Datta et al.,
1999) but also by the Akt-dependent translation and expres-
sion of growth factors, such as VEGF, that promote survival
in an autocrine, and possibly paracrine, fashion. In other
terms, our results reveal that VEGF is a novel target of Akt
signaling by integrins that is important for survival and dis-
tinct from known survival factors that are downstream of
Akt, such as Bad (Datta et al., 1999). Importantly, our recent
observation that VEGF stimulates the PI-3K–Akt pathway in
carcinoma cells (Bachelder et al., 2001), in conjunction with
our finding that  6 4 signaling enhances VEGF expression,
leads to the conclusion that integrin-mediated activation of
PI-3K–Akt is amplified by integrin-stimulated VEGF expres-
sion. Moreover, we show that this amplification of PI-3K–
Akt activity is important for carcinoma survival.
Although  6 4 activates PI-3K in carcinoma cells (Gam-
baletta et al., 2000; Nguyen et al., 2000; Hintermann et al.,
2001; Trusolino et al., 2001), no attempt had been made to
link this signaling event with downstream effectors that reg-
ulate protein translation, namely mTOR and 4E-BP1. One
reason that this possibility had not been explored is because a
role for  6 4 in regulating either protein translation or
growth factor expression was not obvious. In fact, almost all
of the functional studies on  6 4 in carcinoma cells have fo-
cused on its role in promoting migration and invasion, and
on the mechanism by which  6 4-mediated signaling influ-
ences these processes (Mercurio, 1990; Shaw et al., 1997;
Gambaletta et al., 2000; Trusolino et al., 2001). Our moti-
vation to examine a possible connection between  6 4 and
VEGF translation was based on our interest in understand-
ing the mechanisms by which these molecules promote the
survival of carcinoma cells. Indeed, our results establish a
role for  6 4 in survival signaling by regulating VEGF
translation, but the implications of these findings are more
widespread. For example, recent studies that have argued
that  6 4 is necessary for growth factor receptor (erbB2,
c-met) activation of PI-3K (Gambaletta et al., 2000; Truso-
lino et al., 2001) raise the interesting possibility of an inti-
mate functional association among specific growth factor
receptors,  6 4, VEGF, and PI-3K, all of which have been
implicated in tumor progression.
Surprisingly, few studies have examined the role of inte-
grin signaling in regulating protein translation (e.g., Pabla et
al., 1999). Indeed, there has been much more interest in de-
fining the contribution of integrins to transcription. The
ability of integrins to regulate translation, however, provides
a mechanism for altering cell function rapidly, by increasing
the expression of specific proteins. This possibility is exem-
plified by our finding that ligation of the  6 4 integrin re-
sulted in a significant increase in VEGF protein within 60
min (Fig. 2 C). Given the fact that eIF-4E is rate limiting for
the translation of proteins involved in growth control and
other critical cell functions (De Benedetti and Harris, 1999),
the hypothesis can be formulated that integrin-mediated
regulation of translation contributes to the ability of cells to
alter their behavior rapidly in response to changes in their
microenvironment. This hypothesis is particularly relevant
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though much of the work in this area has focused on the
ability of hypoxia to stimulate VEGF transcription and in-
crease the stability of VEGF mRNA (von Marschall et al.,
2001), it has become apparent that translational control is
also important (Kevil et al., 1996; De Benedetti and Harris,
1999). Moreover, our recent finding that VEGF is essential
for the survival of breast carcinoma cells in normoxia sub-
stantiates the functional importance of integrin-mediated
regulation of VEGF expression (Bachelder et al., 2001).
The fact that our data implicate eIF-4E in tumor cell sur-
vival is of considerable interest because recent studies have
revealed an important role for this elongation factor in can-
cer (DeFatta et al., 1999, 2000; Ernst-Stecken, 2000; Berkel
et al., 2001). Overexpression of this factor in NIH3T3 cells,
as well as other “normal” cells, stimulates division and can
induce their transformation (Fukuchi-Shimogori et al.,
1997). These findings are consistent with the reports that
the expression of eIF-4E is elevated in solid tumors com-
pared with normal tissue (De Benedetti and Harris, 1999).
Moreover, hypoxia, a pathophysiological stress that provides
a selective pressure for the survival of aggressive tumor cells,
enhances eIF-4E expression (DeFatta et al., 1999). To-
gether, these observations highlight an important role for
translational control in human cancer. This role is substanti-
ated by the fact that eIF-4E controls the translation of not
only VEGF but also other molecules that influence tumor
growth and survival such as c-Myc, cyclin D1, and FGF-2
(De Benedetti and Harris, 1999). From our perspective, we
are intrigued by the reports that the  6 4 integrin is associ-
ated with the progression of many solid tumors, and its ex-
pression has been correlated with a poorer prognosis in pa-
tients with some of these tumors (Mercurio and Rabinovitz,
2001). Our finding that  6 4 can induce the translational
function of eIF-4E by regulating the phosphorylation of 4E-
BP1 provides one mechanism to account for the role of this
integrin in cancer.
Materials and methods
Cells
MDA-MB-231 and MDA-MB-435 breast carcinoma cells were obtained
from the Lombardi Breast Cancer Depository at Georgetown University.
They were grown in low glucose DME containing 10% FBS, 1% penicil-
lin–streptomycin, and 25 mM Hepes. For inhibitor experiments, cells were
harvested by trypsinization and suspended cells were incubated with rapa-
mycin (Calbiochem) at 100 nM or LY 294002 (Calbiochem) at 10  M on
ice for 30 min before they were plated at 37 C for the experiment.
The generation of MDA-MB-435 subclones expressing the  6 4 inte-
grin has been described previously (Shaw et al., 1997). Tyrosine residue
1494 in the  4 subunit was mutated to a phenylalanine residue using the
Quickchange site-directed mutagenesis kit (Stratagene), and stable sub-
clones of MDA-MB-435 cells that expressed  6 4 containing this mutant
 4 subunit were generated (Shaw, 2001).
For adenoviral infection, cells were grown in DME containing 10% FBS
until they reached 50% confluency. At this point, the culture medium was
changed to DME containing 0.5% FBS. Viral dilutions were prepared from
purified viral stocks in DME containing 0.5% FBS and the cells were in-
fected for 4 h. At the end of the infection period, the virus-containing me-
dium was removed and the cells were washed once with PBS, and incu-
bated for an additional 12 h in DME containing 10% FBS.
Apoptosis assays
To induce apoptosis, cells were incubated in DME containing 0.5% FBS
for 24 h at 37 C. Subsequently, both adherent and nonadherent cells were
harvested and their level of apoptosis was assessed using annexin V–FITC.
In brief, cells were washed once with serum-containing medium, once
with PBS, once with annexin V–FITC buffer (10 mM Hepes-NaOH, pH
7.4, 140 mM NaCl, 2.5 mM CaCl2), and then incubated for 15 min at room
temperature with 5  g/ml annexin V–FITC (Biosource International). After
washing once with annexin V buffer, the samples were resuspended in the
same buffer and analyzed by flow cytometry. Immediately before the anal-
ysis, 5  g/ml propidium iodide (PI) (Biosource International) was added to
distinguish apoptotic cells from necrotic cells.
Quantitative real-time PCR
Quantitative analysis of VEGF mRNA expression was performed by real-
time PCR using an ABI Prism 7700 sequence detection system (Perkin-
Elmer) and SYBR green master mix kit as described previously (Bachelder
et al., 2001). Sequences of primers and probes were as follows: VEGF for-
ward primer, 5 -GAAGTGGTGAAGTTCATGGATGTCTA-3 ; VEGF reverse
primer, 5 -TGGAAGATGTCCACCAGGGT-3 ; VEGF probe, 5 -/TET/
AGCGCAGCTACTGCCATCCAATCG/TAM/-3 ;   -actin forward primer,
5 -TCACCATGGATGATGATATCGC-3 ;  -actin reverse primer, 5 -AAGC-
CGGCCTTGCACAT-3 ; and  -actin probe, 5 -/FAM/CGCTCGTCGTCGA-
CAACGGCT/TAM/-3 .The data obtained are presented as the mean ratio of
VEGF to  -actin mRNA (  SD) obtained from triplicate samples.
VEGF antisense oligonucleotide experiments
A VEGF antisense 2’-O-methyl phosphorothioate oligodeoxynucleotide
(5 -CACCCAAGACAGCAGAA-3 ) and a sense 2’-O-methyl phospho-
rothioate oligodeoxynucleotide (5 -CTTTCTGCTGTCTTGGGTG) (pro-
vided by Greg Robinson, Children’s Hospital, Boston, MA) were used to
transfect MDA-MB-435  4 transfectants at a concentration of 0.3  M in
the presence of lipofectin reagent (2  g/ml; GIBCO BRL). The experimen-
tal details for this approach have been described previously (Bachelder et
al., 2001). In addition, the same protocol was used to express antisense
and sense eIF-4E oligonucleotides, which were gifts from Arigo De Bene-
detti (Louisiana State University, Shreveport, LA) (DeFatta et al., 2000).
RNAi experiments
An RNAi specific for the  4 integrin subunit (GAGCUGCACGGAGUGU-
GUC) as well as the inverted sequence (CUGUGUGAGGCACGUCGAG)
were designed and synthesized by Dharmacon, Inc. MDA-231 cells at
30% confluency were transfected with 300 pmoles of RNAi using TKO
lipids (Mirus). Subsequently, the cells were maintained in complete me-
dium for 72 h and in medium containing 0.5% FBS for an additional 24 h
before analysis.
Polysome analysis
Cells (3   10
7) were maintained in medium containing low serum (0.5%
FBS) for 24 h and then pretreated with 100  g/ml cycloheximide (Calbio-
chem) for 15 min at 37 C before being harvested. After washing once with
PBS containing 100  g/ml cycloheximide, the cells were resuspended in
0.5 ml of a modified U S buffer (Davies and Abe, 1995). This buffer was
composed of 200 mM Tris-HCl (pH 8.8), 25 mM MgCl2, 5 mM EGTA (pH
8.0), 150 mM KCl, 10  g/ml heparin, 5 mM DTT, 1% sodium deoxycho-
late, 2% polyoxyethylene 10-tridecy ester, 100  g/ml cycloheximide, and
200 mM sucrose. Ribonuclease inhibitor (Amersham Biosciences) was
added to a final concentration of 0.5 U/ l. Cells were homogenized with
20–25 strokes in a Kontes tissue homogenizer, followed by centrifugation
for 5 min at 14,000 g. The supernatant was collected and frozen at  80 C
until further use. Sucrose gradients (15–50%, wt/wt) were layered with 300
 l of cleared cell extract, which was then centrifuged at 160,000 g for 2 h.
Fractions (0.75–0.375 ml) were withdrawn from the top of the gradient and
monitored for absorbency at 254 nm using an ISCO syringe pump with
UV-6 detector. Total RNA from the sucrose gradient fractions was ex-
tracted using Trizol LS (Life Technologies) according to the manufacturer’s
instructions. Quantitative real-time PCR was used to measure the VEGF
mRNA level in each fraction as described above.
Integrin signaling experiments
Cells were harvested by trypsin treatment and washed twice with DME
containing 25 mM Hepes and 0.1% BSA. After washing, the cells were re-
suspended in the same buffer at a concentration of 2   10
6 cells/ml and in-
cubated for 30 min with integrin-specific antibodies (4  g/ml) or with ei-
ther mouse or rat IgG (4  g/ml). The cells were washed once, resuspended
in the same buffer, and added to plates that had been coated overnight
with either the anti–mouse or rat IgG. After a 60-min incubation at 37 C,
the cells that had attached to integrin-specific antibodies were washed
twice with cold PBS and solubilized at 4 C for 10 min using RIPA buffer
(20 mM Tris buffer, pH 7.4, containing 0.14 M NaCl, 1% NP-40, 10%
glycerol, 1 mM sodium orthovanadate, 2 mM PMSF, 5  g/ml aprotinin, Integrin ( 6 4) regulation of VEGF and carcinoma survival | Chung et al. 173
pepstatin, and leupeptin). The IgG-treated cells were harvested by centrifu-
gation and solubilized with RIPA buffer.
Protein analysis
Aliquots of cell extracts containing equivalent amounts of protein were
solubilized using 5  sample buffer containing 100 mM DTT and then in-
cubated at 100 C for 15 min. These extracts were resolved by SDS-PAGE
and transferred to nitrocellulose filters. The filters were blocked for 1 h us-
ing a 50 mM Tris buffer, pH 7.5, containing 0.15 M NaCl, 0.05% Tween-
20 (TBST), and 5% (wt/vol) Carnation dry milk. The filters were incubated
overnight in the same buffer containing antibodies specific for p70S6K,
4EBP antibodies (Santa Cruz Biotechnology, Inc.), actin (ICN Biomedicals),
and VEGF (clone 618, provided by Donald Senger, Beth Israel Deaconess
Medical Center). After three, 10-min washes in TBST, the filters were incu-
bated for 1 h in blocking buffer containing HRP-conjugated secondary an-
tibodies. After three 10-min washes in TBST, proteins were detected by
ECL (Pierce Chemical Co.).
For immunoblots involving phosphospecific antibodies, the filters were
blocked for 1 h using a 10 mM Tris buffer, pH 7.5, containing 0.5 M NaCl,
0.1% Tween-20, and 2% (wt/vol) BSA. The filters were washed briefly and
then incubated overnight at 4 C in the same blocking buffer containing an-
tibodies specific for phospho-p70S6K (Thr-389; Cell Signaling Technol-
ogy), phospho–4E-BP1 (Ser-65; Cell Signaling Technology), phospho-Erk
(E10; Cell Signaling Technology), and phospho-Akt (Ser-473 clone 4E2;
Cell Signaling Technology). After washing, the filters were incubated for 1 h
in blocking buffer containing HRP-conjugated secondary antibody and the
proteins were detected by ECL.
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